Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALC-2203 in acute bronchitis
NCT07061925Phase 2Completed
- Sponsor
- Korea Arlico Pharm
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
A Phase 2 trial of ALC-2203 in acute bronchitis, sponsored by Korea Arlico Pharm. Started Apr 2025; status: completed.
02
Drugs
ALC-2203
03
Conditions
acute bronchitis
Beyond the preview
Go deeper on NCT07061925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07061925.